FDA Approves Studies of Plasma Therapy for COVID-19: Columbia University
April 24, 2020
April 24, 2020
NEW YORK, April 24 -- Columbia University's Mailman School of Public Health issued the following news:
The U.S. Food and Drug Administration has granted approval to the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health to launch clinical trials to determine whether blood plasma from COVID-19 survivors can be used to prevent infections in unexposed healthcare workers and first responders, high-risk individuals, and close contacts of COVID- . . .
The U.S. Food and Drug Administration has granted approval to the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health to launch clinical trials to determine whether blood plasma from COVID-19 survivors can be used to prevent infections in unexposed healthcare workers and first responders, high-risk individuals, and close contacts of COVID- . . .